Variables | Total N (%) |
---|---|
Sex (Female) | 74 (49.3) |
Age (years), Mean ± SD, min - max | 42.7 ± 12.1; 18–70 |
≤ 35 | 45 (30.0%) |
> 35–45 | 51 (34.0%) |
> 45–55 | 29 (19.3%) |
> 55 | 25 (16.7%) |
Highest Education | |
Primary school | 20 (13.3) |
High school or vocational education | 76 (50.7) |
Higher education | 54 (36.0) |
Employment | 86 (57.3) |
Monthly income (USD) a | |
No salary | 33 (22.0) |
≤ 157 | 46 (30.7) |
> 157–313 | 34 (22.7 |
> 313 | 37 (24.7) |
Duration of illness (years), Median (IQR); min - max | 11 (5, 20); 8 days – 40 years |
< 10 | 56 (37.3%) |
11–20 | 54 (36.0%) |
> 20 | 40 (26.7%) |
History of hospitalization (time), Median (IQR); min - max | 1 (1, 3), 1–10 |
Never | 64 (42.7) |
At least one time | 46 (30.7) |
More than one time | 40 (26.7) |
Current antipsychotic treatment | 147 (98.0) |
Types of antipsychotic drug | |
Typical antipsychotic drug | 63 (42.0) |
Atypical antipsychotic drug | 40 (26.7) |
Both types of drug | 44 (29.3) |
Not currently received medication | 3 (2.0%) |
Routes of medication | |
Oral | 128 (85.3) |
Intramuscular | 2 (1.3) |
Both | 17 (11.3) |
Not currently received medication | 3 (2.0%) |
CPZ equivalent daily dose (mg), Median (IQR); min-max | 300 (150,500); 25–1004 |
≤ 100 | 26 (17.3%) |
> 100–250 | 43 (28.7%) |
> 250–500 | 51 (34.0%) |
> 500 | 27 (18.0%) |
Not currently received medication | 3 (2.0%) |
Common medication side effects | 52 (34.7) |
Drowsiness | 18 (34.6) |
Weight gain | 10 (19.2) |
Dizziness | 6 (11.5) |